Glenbrook Capital Management purchased 30,000 common shares of SenesTech Inc., increasing its indirect holdings to over 2.1 million shares. The firm holds warrants for an additional 180,000 shares, cu
Glenbrook Capital Management filed a Form 4 report detailing insider transactions for SenesTech Inc on October 20, as the company's stock rose 5.77%.
Glenbrook Capital Management acquired a 38.04% stake in SenesTech for $4.33 million and may recommend board changes following an amended Schedule 13D filing.
Glenbrook Capital Management disclosed a stake exceeding 30% in SenesTech following 40% Q3 revenue growth. The firm cites undervaluation and insider optimism despite ongoing losses.
Glenbrook Capital Management acquired over a 30% stake in SenesTech, pushing for marketing and capital allocation changes, including equity-based compensation, despite the company's recent 40% top-lin
Glenbrook Capital Management has acquired over 30% of SenesTech, urging improved market strategy and capital discipline while engaging Sandstrom Partners for branding assistance.
SenesTech secured a new sales channel with Grove Collaborative for its Evolve rodent birth control products, driving Q2 revenue up 56.19% to USD 770,000 despite a net loss.
SenesTech announced its Evolve rodent birth control products will be available on Grove Collaborative's online marketplace, expanding distribution to sustainability-focused consumers. This strategic m
Glenbrook Capital Management purchased 21,490 SenesTech shares at $1.297 per share, increasing its indirect holding to 1,079,294 shares without a Rule 10b5-1 plan.
Glenbrook Capital Management acquired a 19.95% stake in SenesTech for approximately $3.6 million, viewing the ag-biotech firm as undervalued and planning active engagement with its management.
Glenbrook Capital Management acquired a 19.95% activist stake in SenesTech, switching to Schedule 13D to influence strategy and operations while funding marketing initiatives.
SenesTech reports significant insider buying from 10% owner Glenbrook Capital, signaling confidence despite earnings misses. The company is undergoing strategic transformation with a new CEO focusing
Glenbrook Capital Management increased its holdings in SenesTech Inc. by purchasing 25,416 shares in late June 2026, totaling $39,102.
Glenbrook Capital Management purchased 25,416 shares of SenesTech Inc. (NASDAQ: SNES) for $39,102 in late June 2026, raising its total holding to 987,824 shares near the stock's 52-week low.
Glenbrook Capital, a 10% shareholder of SenesTech, purchased $13,563 worth of common stock in June, increasing its holdings despite the company's 55.7% stock decline over the past year.
Glenbrook Capital Management increased its stake in SenesTech Inc. by purchasing $45,535 worth of shares, raising total holdings to 954,144 shares alongside reported Q1 revenue growth.
Glenbrook Capital Management purchased $53,486 worth of SenesTech Inc. shares, increasing holdings to 925,755 shares amidst Q1 revenue growth.
Glenbrook Capital Management increased its indirect holdings in SenesTech Inc by purchasing 32,120 shares in May 2026, raising total holdings to over 925,000 shares.
Glenbrook Capital Management increased its holdings in SenesTech Inc. by purchasing 3,000 shares near the 52-week low. SenesTech reported a 20% revenue increase in fiscal year 2025 driven by e-commerc
Glenbrook Capital Management entities purchased 3,000 SenesTech shares at $1.469/share, increasing their indirect holding to 893,635 shares.
Glenbrook Capital Management disclosed a 16.8% beneficial ownership stake in SenesTech Inc through affiliated vehicles. The filing indicates shared voting power over 890,635 shares based on March 11,
SenesTech reported Q4 2025 earnings with a 15.97% revenue drop to $421,000 and continued net losses, despite a 479% surge in cash reserves, leading to a 4.27% stock decline.
ChemBrief